retatrutide fda approval status as of october 2025 βοΈ Introducing β’ R E T A T R U T I D E β’ for Weight Loss π©· Advanced Mobile IV Baltimore is excited to share the next generation in weight Covering Every FDA Oncology Approval
Description
Stick to one and let it do its thing!

Tirzepatide achieved comparable results through weight loss, without requiring a machine, a mask, or nightly compliance

2025 [cited 2025 Aug 16]

doi: 10.1002/osp4.22
10.18632/oncotarget.9277 Oncotarget 34 RosellA.LoE

A separate In a large cohort of patients with type 2 diabetes, researchers found that GLP-1 use was not associated with a higher incidence of NAION but was linked to another eye condition: diabetic retinopathy